Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Buyout at these levels.

<< Previous

Bullboard Posts

Next >>

Comment by bazooka73on Oct 18, 2022 9:38am

89 Views

Post# 35031052

RE:RE:RE:RE:Buyout at these levels.

Turtle4 wrote: Abbvie conducted a very long and intensive due diligence. And the result was: it is not worth it. Sirona management will accept any license offer, no matter how cheap, so there is no reason for a takeover. They just have to make sure there is no competition, so they fund the studies for a right of first refusal.

Long and intensive due diligence yes, but it was not stated if that was done only for 1067 (what I assume) or for the whole company

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China